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Abstract 167 words. 
 
Cancer cachexia is a devastating syndrome occurring in the majority of terminally-ill cancer patients. 
Notably, skeletal muscle atrophy is a consistent feature affecting the quality of life and prognosis. To 
date, limited therapeutic options are available, and research in the field is hampered by the lack of 
satisfactory models to study the complexity of wasting in cachexia-inducing tumors, such as 
pancreatic cancer. Moreover, currently used in vivo models are characterized by an explosive cachexia 
with a lethal wasting within few days, while pancreatic cancer patients might experience alterations 
long before the onset of overt wasting. In this work, we established and characterized a slow-paced 
model of pancreatic cancer-induced muscle wasting that promotes efficient muscular wasting in vitro 
and in vivo. Treatment with conditioned media from pancreatic cancer cells led to the induction of 
atrophy in vitro, while tumor-bearing mice presented a clear reduction of muscle mass and 
functionality. Intriguingly, several metabolic alterations in tumor-bearing mice were identified, paving 
the way for therapeutic interventions with drugs targeting metabolism. 
 
 
 
 Introduction 
 
More than half of cancer patients are suffering from a systemic wasting disorder referred to as 
cachexia (from Greek “bad condition”), a syndrome strongly affecting the quality of life and 
prognosis in cancer patients. This syndrome is characterized by unstoppable consumption of adipose 
and skeletal muscle tissues leading to an excessive body weight loss that cannot be fully reverted by 
conventional nutritional support1. !
Cancer cachexia is a complex syndrome accounting for multiple organ dysfunction and 
systemic metabolic deregulations2. Cachectic patients experience symptoms ranging from anorexia, 
elevated inflammation, insulin resistance, and increased energy expenditure, which ultimately 
promote malaise, fatigue, and impair tolerance to chemotherapy3, further worsening patients’ 
prognosis. Besides being associated with a poor prognosis, cachexia is estimated to be the direct cause 
of one-third of cancer deaths"#! Several tissue dysfunctions emerge during cachexia, such as liver 
steatosis, fat deposit lipolysis, intestinal dysbiosis, and, most notably, skeletal muscle wasting, which 
accounts for the steep decrease in quality of life, weakness, and respiratory distress of cancer patients. 
Skeletal muscle atrophy is a highly regulated process driven by an unbalance between protein 
synthesis and degradation. Activation of the ubiquitin-dependent proteasome pathway (UPP), as well 
as the autophagy-lysosome system, are two important mechanisms leading to increased protein 
breakdown. This process is orchestrated by a set of genes called atrogenes, such as Atrogin-1/MAFbx 
or Murf15. Compelling evidence shows that impairment of mitochondrial metabolism and increase in 
mitochondrial ROS are also strongly associated with the cachectic phenotype6, 7. 
Several tumor types, such as lung, gastrointestinal tract, and pancreatic cancer, are emerging 
as strong promoters of cancer cachexia8. In particular, pancreatic ductal adenocarcinoma (PDAC) 
presents a high penetrance of wasting, a process that seems to occur even in earlier phases of tumor 
transformation9. Despite the burden of cachexia in PDAC, there are still limited experimental models 
available.  
 
Particularly, our understanding of the biology underlying cachexia is mostly based on the 
extensively used and well characterized C26 carcinoma model, in which mice are drastically losing 
muscle and total body weight in a short period10, thus contrasting with the progressive wasting 
occurring in the human pathology. It is known that C26 model is associated with high levels of IL6 
that play a central role in mediating muscle wasting11, even though other inducers are probably 
involved in cachexia. In order to better characterize early stages of cachexia, we established a model 
of pancreatic cancer-induced cachexia able to promote mitochondrial metabolic alterations and a 
progressive wasting both in vivo and in vitro.  
 
 
 
 
 
  
 Results 
Establishment of a slow-paced cancer-induced muscle wasting model. 
PDAC is known to induce muscle wasting with high penetrance 3. Since cancer cachexia is a complex 
syndrome involving various pathological processes promoting wasting, such as anorexia and chronic 
inflammation, it is difficult to assess the direct contribution from the tumor. Therefore, we decided to 
assess the direct role of cancer cells on skeletal muscle atrophy via an in vitro model of atrophy, thus 
excluding other systemic confounding atrophic factors, hypothesizing that, in this type of cancer, 
atrophy can be mediated directly by tumor cell-secreted factors. 
To this aim, we took advantage of KPC cells, a stable cell line derived from spontaneous primary 
tumor arisen in C57BL/6 KRASG12D P53R172HPdx-Cre+/+ (KPC) mouse12, a genetically modified mouse 
model known to develop spontaneous wasting9. Similarly to other cancer models13, in our 
experimental conditions, KPC cells were able to directly promote muscle atrophy in vitro. Treatment 
of C2C12-derived myotubes with 10% KPC cells conditioned media induced a consistent reduction of 
myotube thickness, similar to that elicited by dexamethasone, used as a positive control of atrophy 
induction (Figure 1A). Reduction in fiber thickness was associated with higher ROS generation 
(Figure 1B). A recent report from Michaelis et al.12 showed that a subcutaneous injection of 5 millions 
of these cells consistently promotes anorexia, hormonal dysfunctions, and lethal cachexia in 2 weeks. 
In order to establish a progressive model of wasting, we subcutaneously injected 0.7 million of KPC 
cells, which is the minimal amount able to consistently induce tumor growth without exacerbating 
factors such as excessive tumor burden and anorexia. Indeed, 5 weeks after KPC cell injection, neither 
food intake alteration (Figure 1C) nor macroscopic features of wasting were observed, despite a non-
significant trend of decrease in body weight (Figure 1D). Tumor weight at the end of experiment was 
approximatively 0.6 grams (Figure 1E), while in the other work weight was between 1 and 2 grams12. 
Remarkably, despite the absence of overt signs of cachexia, skeletal muscle functionality, checked by 
Rotarod evaluation twice a week (not shown), was drastically affected, but only at week 5, the week 
of the sacrifice. Accordingly, tumor-bearing mice showed reduced muscle performance, as assessed 
by hanging-wire test14 (Figure 1F), suggesting muscle deterioration in tumor-bearing animals. Along 
with reduced performance in stamina-related assays, mice displayed as well a reduction in grip 
strength, indicating that also the maximal force developed was reduced (Figure 1G). 
Coherently with the decrease in muscle functionality, 5 weeks after KPC injection, mice presented a 
consistent loss of gastrocnemius mass of roughly 20% (Figure 2A). The decrease was related to a 
reduction in average fiber size as detailed by histological analysis (Figure 2B-D). Coherently, analysis 
of fiber cross-sectional area (CSA) distribution highlighted a shift towards smaller areas (Figure 2E). 
Reduction in muscle mass was not associated with transcriptional regulation of atrogenes Atrogin1, 
Musa, and Murf1, and of Cathepsin L (Figure 2F-I), nor altered expression of ATG7, BECLIN1, and 
LC3 in gastrocnemii (not shown). Nevertheless, muscle protein lysates presented increased protein 
ubiquitination (Figure 2J), indicative of an activation of the UPP. Along with increased protein 
ubiquitination, we identified higher AMPK phosphorylation, in line with the emerging role of AMPK 
as a functional player in cancer cachexia15.  
 
 
 
Mice undergoing muscle dysfunction present altered lipid metabolism. 
Given the importance of energy metabolism in regulating skeletal muscle mass and functionality16, 17, 
we investigated potential alterations of mitochondrial metabolism in the skeletal muscle of KPC-
bearing mice. To this aim, we assessed basal complex II activity in gastrocnemii by performing 
succinate dehydrogenase (SDH) activity assay. Intriguingly, gastrocnemius sections from KPC-
bearing animals presented increased complex II activity, as evidenced by the increased concentration 
of blue tetrazolium salt (Figure 3A). However, this increased activity was not coupled with elevated 
flux through the electron-transport chain (ETC). Indeed, ETC, as measured by Cytochrome C 
reduction rate in uncoupled mitochondria, was similar in the two groups (Figure 3B). 
While SDH activity supports ETC, it is also part of tricarboxylic acid (TCA) cycle, and it is linked to 
fatty acids oxidation, allowing ketone bodies generated by acetyl coenzyme A due to excessive fatty 
acid oxidation, to enter the TCA. 
To clarify whether the increased SDH activity was indicative of increased fatty acid oxidation, we 
measured this metabolic pathway in isolated mitochondria from the gastrocnemius of either control or 
KPC-bearing mice and we observed a significant increase in fatty acid oxidation in muscles of tumor-
bearing mice (Figure 3C), consistent with the increase in complex II activity. 
In order to identify if the altered intramuscular lipid oxidation was correlated to a systemic 
dysregulation during this pre-cachectic process, we performed T1-weighted Magnetic Resonance 
Imaging (MRI). Intriguingly, 4 weeks post KPC injection (one week before sacrifice), pre-cachectic 
mice presented reduced bright hyper-intensity regions, indicative of reduced fat deposits (Figure 3D-
E). 
Coherently, at the time of sacrifice, KPC-bearing mice presented a significant reduction of inguinal 
fat tissue mass (Figure 3F). Therefore, we speculated that the reduced fat content might be related to 
increased fatty acid oxidation, a feature previously associated with cancer cachexia16 in other tumor 
types.  
High SDH activity18, 19 and excessive fatty acid oxidation might lead to ROS accumulation20, 
ultimately promoting mitochondrial dysfunction21 and fiber damage. Hence, we investigated the 
impact of tumor growth on mitochondrial ROS and energetic balance. Mitochondria extracted from 
KPC-bearing animals had indeed increased ROS (Figure 3G), coupled with reduced ATP (Figure 3H), 
suggesting that the increased fatty acid oxidation may have a detrimental rather than beneficial effect 
on mitochondria. 
 
Materials and Methods 
Animals 
Young adult female (9-12 weeks old) C57BL/6J mice were used. All animal experiments were 
authorized by the Italian Ministry of Health and carried out according to the European Community 
guiding principles in the care and use of animals. 
 
Generation of PDAC model 
KPC tumor cells were derived from a primary culture of pancreatic tumour cells of the Genetically 
Engineered Mouse Model of PDAC  K-rasLSL.G12D/+; p53R172H/+; Pdx-Cre ( KPC). 
 0.7x106 KPC cells in 200!l PBS were injected subcutaneously into the flank of C57bl/6J mice. Mice 
were sacrificed 5 weeks after injection, when tumor volume was approaching 5mm of radius.  
 
In vivo assessment of muscular strength 
Grip test – An automatic grip strength meter was used to measure the maximum forelimb grip 
strength of mice. The machine measures the peak resistance force of the mouse while the latter is 
pulled away from the grid of the device.  Each animal was assessed several times and the final value 
corresponds to the average of 5 repeated force measurements in order to minimize procedure-related 
variability.  
Hanging test  – Wire-hanging test was used to assess whole-body muscle strength and endurance. The 
test was performed as previously described14. Briefly, mice were subjected to a 180 seconds hanging 
test on a wire, during which “falling” and “reaching” scores were recorded. When a mouse fell from 
the wire, falling score was diminished by 1 and when a mouse reached one of the side of the wire, 
reaching score was increased by 1. A final score was then established using both falling and reaching 
scores and was represented in the form of a Kaplan-Meier-like curve; score have been normalized 
with respect to control.  
 
MRI 
Magnetic resonance images were acquired on a 1 Tesla M2 system (Aspect, Israel) equipped with a 
30-mm transmitter/receiver (TX/RX) solenoid coil to determine body composition22. T1-weighted 
Spin-Echo images were acquired with high-resolution whole-body coronal orientation (repetition 
time/echo time/flip angle/number excitations [TR/TE/FA/NEX] 400 ms/9.5 ms/90°/3; field of view 
[FOV] 10 cm, matrix 192x192, number of slices: 18, slice thickness: 1.5 mm, in-plane spatial 
resolution: 521 !m, acquisition time: 4min). All T1-weighted images were processed by an in-house 
Matlab-developed script (MATLAB R2008, The MathWorks Inc.). The T1-weighted image histogram 
has three dominating classes, background, lean mass and fat, so the total fat volume was isolated by 
segmenting the image into three categories by using a k-means clustering algorithm23, 24. 
 
 
Gene expression analysis 
Gastrocnemii were harvested, frozen in liquid nitrogen, and crushed. Total RNA was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA). cDNA was synthesized from 1000 ng of total RNA using 
cDNA reverse transcription kits (Applied Biosystems, Foster City, CA). Relative mRNA level was 
analyzed by real time PCR (ABI 7900HT FAST Real-Time PCR system, Applied Biosystems, Foster 
City, CA) with TaqMan assays, using the Universal Probe Library system (Roche Applied Science, 
Penzberg, Germany). 18S gene was used as housekeeping control. The following primers were used: 
FBX030 (MUSA1) F:5’-gagaagccagggtttgagc-3’ R: 5’-tcatacagtgtgagtgctgctg-3’ ; FBX032(atrogin 1) 
F:5’-agtgaggaccggctactgtg-3’ R: 5’-gatcaaacgcttgcgaatct-3’ ; TRIM63 (MuRF1) F:5’-
tgacatctacaagcaggagtgc-3’ R: 5’-tcgtcttcgtgttccttgc-3’ ; Cathepsin L F:5’-caaataagaataaatattggcttgtca-
3’ R:5’-tttgatgtagccttccataccc-3!.  
 
Western Blot 
Protein samples from gastrocnemius were extracted with RIPA lysis buffer (150 mM NaCl, 50 mM 
Tris-HCl, 0.5% sodium deoxycholate, 1.0% Triton X-100, 0.1% SDS 1 mM EDTA) supplemented 
with protease and phosphatase inhibitor cocktail (Roche). Protein concentration was determined using 
BCA protein assay (Thermo Fisher Scientific). Lysates were subjected to SDS-PAGE and then 
transferred to PVDF membrane for immunoblotting analysis. The following antibodies were used: 
mono- and polyubiquitin (BML-PW8805, Enzo Life Sciences, 1:1000), p-AMPK (2535, Cell 
Signaling, 1:1000), "-actin (4967, Cell Signaling, 1:1000). 
 
Tissue collection and histology 
Gastrocnemius muscle was excised, weighted, frozen in isopentane cooled in liquid nitrogen, and 
stored at -80°C. Transverse sections (7!m) from the medial belly were cut on a cryostat and collected 
on Superfrost plus glass slides. Cryosections were then processed for laminin staining. In detail, 
sections were fixed in 4% paraformaldehyde (PFA) for 10 min before being incubated with laminin 
antibody (1:200; Dako) and visualized by anti-mouse IgG Alexa Fluor 488 (Thermo Fisher Scientific) 
secondary antibody. Pictures of whole slides were acquired with the slide scanner Pannoramic Midi 
1.14 (3D Histech, Budapest, Hungary) and cross sectional area (CSA) was measured automatically by 
ImageJ software.  
 
Succinate dehydrogenase activity 
Succinate dehydrogenase (SDH) enzymatic activity was determined on 15!m cryosections by specific 
staining (Bio-Optica, Milan, Italy) following the producer’s instructions. Briefly, the cryosections 
were incubated with the rehydrated SDH solution for 45 min at 37°C, washed, fixed, and mounted on 
slides. Images were then acquired with the slide scanner Pannoramic Midi 1.14.   
 
Cell culture and conditioned media (CM) preparation 
C2C12 cells were cultured in DMEM /10% FBS and differentiated in DMEM/ 2% horse serum (HS) 
for 4 days as reported previously25. KPC cells were derived from a primary culture of pancreatic 
tumor cells of the Genetically Engineered Mouse Model of PDAC K-rasLSL.G12D/+; p53R172H/+; PdxCre 
mice (KPC). 
Conditioned medium (CM) was prepared as following: KPC cells were grown in DMEM with 10% 
FBS supplemented with 1% penicillin and streptomycin. When cells reached full confluence, medium 
was removed; cells were washed twice with phosphate buffered saline (PBS) and once with serum-
free DMEM. Cells were grown in serum-free DMEM for further 24h, then the medium was collected, 
centrifuged at 4000 rpm for 10 min, aliquoted, and stored at -80°C. Atrophy on C2C12 was induced 
with 10% CM treatment for 48h. 
 
 
Myotube diameter quantification 
C2C12 myotubes were treated with differentiation medium supplemented with 10% conditioned 
medium from KPC for 48 h. Pictures of myotubes were taken with bright field microscopy (Zeiss), 
and diameters of myotubes were measured using the software JMicroVision as previously described25. 
 
ROS measurement in vitro 
ROS production was assessed in C2C12 myotubes  by using the oxidant-sensitive fluorescent dye 
29,79-dichlorodihydrofluoroscein diacetate (H2DCFDA; Molecular Probes, Inc., Eugene, OR). Cells 
were incubated with 10 !M H2DCFDA in PBS for 30 minutes at 37°C under 5% CO2 atmosphere in 
darkness. Excess probe was washed out with PBS. Fluorescence was recorded at excitation and 
emission wavelengths of 485 nm and 530 nm, respectively, by a fluorescence plate reader (Promega). 
Fluorescence intensity was expressed as arbitrary units. 
 
Mitochondria isolation 
Mitochondrial fractions were isolated as previously reported26, with minor modifications. Samples 
were lysed in 0.5 mL buffer A (50 mM Tris, 100 mM KCl, 5 mM MgCl2, 1.8 mM ATP, 1 mM EDTA, 
pH 7.2), supplemented with protease inhibitor cocktail III (Calbiochem), 1 mM PMSF, and 250 mM 
NaF. Samples were clarified by centrifuging at 650 x g for 2 min at 4°C, and the supernatant was 
collected and centrifuged at 13,000 x g for 5 min at 4°C. This supernatant was discarded and the pellet 
containing mitochondria was washed in 0.5 mL buffer A and resuspended in 0.25 mL buffer B (250 
mM sucrose, 15 mM K2HPO4, 2mM MgCl2, 0.5 mM EDTA, 5% w/v BSA). A 50 µL aliquot was 
sonicated and used for the measurement of protein content or Western blotting; the remaining part 
was stored at -80°C.  
 
Electron transport chain 
The activity of Complex I–III was measured on 25 !L of non-sonicated mitochondrial samples 
resuspended in 145 !L buffer C (5 mM KH2PO4, 5 mM MgCl2, 5% w/v BSA) and transferred into 96-
well plate. Then, 100 !L buffer D (25% w/v saponin, 50 mM KH2PO4, 5 mM MgCl2, 5% w/v BSA, 
0.12 mM cytochrome c-oxidized form, 0.2 mM NaN3) was added for 5 min at room temperature. The 
reaction was started with 0.15 mM NADH and was followed for 5 min, the absorbance was measured 
at 550 nm by a Synergy HT Spectrophotometer (Bio-Tek Instruments). Under these experimental 
conditions, the rate of cytochrome c reduction, expressed as nmol cyt c reduced/min/mg 
mitochondrial proteins, was dependent on the activity of both Complex I and Complex III27. 
 
Intramitochondrial ATP levels 
The amount of ATP was measured on 20 µg of mitochondrial extracts with the ATPlite assay 
(PerkinElmer), according to the manufacturer’s instructions. Data were converted into nmoles/mg 
mitochondrial proteins, using a calibration curve previously set. 
Intramitochondrial ROS levels 
The amount of ROS in mitochondrial extracts was measured fluorimetrically incubating 
mitochondrial suspension at 37°C for 10 minutes with 10 !M of  
5-(and-6)-chloromethyl-2,7-dichorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-AM), 
then washed and resuspended in 0.5 mL of PBS. Results were expressed as nmoles/mg mitochondrial 
proteins, using a calibration curve previously set with serial dilution of H2O2. 
 
Fatty acids !-oxidation 
Long-chain fatty acids were measured as described by Gaster et al28 with minor modifications. 100 !l 
mitochondrial suspension were rinsed with 100 !l of 20 mM HEPES, containing 0.24 mM fatty acid-
free BSA, 0.5 mM L-carnitine, and 2 !Ci [1-14C]palmitic acid (3.3 mCi/mmol, PerkinElmer). Samples 
were incubated at 37°C for 1 h, then 100 !l of 1:1 v/v phenylethylenamine 100 mM/methanol solution 
were added. After one hour at room temperature, the reaction was stopped by adding 100 !L of 0.8 N 
HClO4. Samples were centrifuged at 13,000 x g for 10 min. Both the precipitates containing 14C-acid 
soluble metabolites (ASM) and the supernatants containing 14CO2-derived from oxidation (used as 
internal control and expected to be less than 10% of ASM) were counted by liquid scintillation. 
Results are expressed as nmol/min/mg cellular proteins.  
 
Statistics 
Statistical significance was evaluated with one-way or two-way analysis of variance (ANOVA) for 
multiple groups, followed by post-hoc test as defined in the figure legends. Student’s unpaired t-test 
was used to compare two groups. All error bars indicate SEM. Significance was established as 
P<0.05. Data have been obtained from multiple independent experiments for in vitro assay and from 
at least 4 mice for in vivo experiments. All the analyses were performed with the software PRISM5 
(GraphPad Software). 
 
 
Discussion 
 
Pancreatic cancer is a pathology with dismal prognosis associated with a stark decrease in quality of 
life, mostly because of cachexia development29 30. While cachexia is considered as the last step of 
cancer progression,  it is important in PDAC to model the earliest steps of the disease (i.e., pre-
cachexia). Indeed, Mayers et al.9 found that spontaneous PDAC mouse model presents an increased 
release of amino acids from the skeletal muscle months before the development of cachexia, which is 
consistent with data from PDAC patients9. These data advocate for the importance of defining 
alterations in skeletal muscle occurring in the early phases of disease, before the establishment of 
overt cachexia. 
To this aim, we modified the cancer cachexia model described by Michaelis et al. to reproducibly 
induce cachexia with KPC cells12. Since KPC-bearing male mice present hormonal dysfunctions, we 
performed the study in female mice, although these animals are characterized by a moderate degree of 
wasting. While Michaelis and coworkers modeled cachexia by injecting up to 5 x 106 cells per mouse, 
thus promoting anorexia and subsequent animal death starting from 11-14 days, we injected only 0.7 x 
106 cells (the minimal amount necessary to consistently promote tumor growth) in order to promote a 
slower tumor growth, thus allowing the characterization of pre-cachectic events. This reduced cell 
number resulted in barely palpable tumors at 2 weeks after injection (the time point where mice from 
Michaelis et al. already started to die of cachexia). Moreover, in contrast to the effects reported with 
the injection of higher amount of KPC cells, smaller tumor mass (up to 75% reduction) and no effect 
on heart weight were observed (data not shown). 
Despite the moderate degree of wasting, mice presented reduced muscle function and strength. In 
order to detect alterations in muscle morphology occurring at early phases of wasting, we sacrificed 
the mice at the first sign of decreased performance. At necropsy, mice presented a statistically 
significant reduction in gastrocnemius weight and fat deposit, but no signs of anorexia, excluding an 
involvement of food intake in the skeletal muscle mass reduction. Intriguingly, we found only a trend 
towards decreased body weight, similarly to the findings of Brown and colleagues7. Of note, it is 
known that many tumors hijack organ function, especially liver and spleen3, by inducing increased 
organ size, which might counterbalance the drop in muscle and fat in the first phases. Muscle from 
tumor-bearing mice did not present any major transcriptional regulation of the investigated atrogenes. 
However, we identified increased levels of AMPKT172 phosphorylation, indicative of ongoing energy 
stress, and protein ubiquitination indicating that the alterations present in muscle were mediated by a 
different pathway, i.e., alternative ubiquitin ligase, a regulation at protein level, or alterations in 
protein deubiquitinases. 
As previously shown in clear cell kidney cancer, muscle undergoing wasting is causally linked to 
increased fatty acid oxidation16, 31, potentially raising noxious ROS generation in the mitochondria. 
Noteworthy, also in our model the significant drop in lipid was coupled with an increased fatty acid 
utilization and mitochondrial ROS generation, indicating a potential source of oxidative stress causing 
reduced muscular function and degeneration. Intriguingly, we identified an increased activity of SDH, 
uncoupled from increased ETC flux. Moreover, ATP content was decreased, suggesting  a profound 
mitochondrial alteration. This observation further supports the concept that mitochondrial alterations 
occur at the early phases of cachexia. While SDH does not contribute to increasing mitochondrial 
energy metabolism in cachectic muscles, it promotes the metabolism of ketone bodies-derivatives that 
are produced in conditions of high fatty acid oxidation, i.e., in the same metabolic conditions of KPC-
bearing muscles. Redox cycles occurring at Complex I and Complex III of ETC are generally 
considered as the key sources of ROS within mitochondria32. However, also SDH complex has been 
recognized as an important source of intra-mitochondrial ROS18. Taken together, our findings suggest 
that muscles consume fatty acids, forcing SDH activity in early cachexia. The final result is an 
energetic catastrophe that may severely impair muscle physiological performance. 
Interestingly, in vitro myotubes did not show increased fatty acids oxidation during atrophy (not 
shown), in line with the fact that culture and differentiation media contain limited amount of fatty 
acids. However, C2C12 cells treated with the medium of pancreatic cancer cells displayed the same 
alterations observed in cachectic muscles, i.e., high ROS levels and AMPK phosphorylation (not 
shown), suggesting that common metabolic alterations in mitochondrial metabolism occur in the early 
phase of cachexia both in vitro and in vivo.    
In conclusion, we report a novel model of pre-cachexia causing a drastic reduction of muscle function 
and initial reduction of skeletal muscle mass. Interestingly, the onset of increased fatty acid oxidation 
and mitochondrial ROS generation occurs before the emergence of muscle mass reduction. Further 
test inhibiting fatty acid oxidation or mitochondrial ROS generation will be instrumental in 
understanding the relative contribution of such pathways to the pathogenesis of cachexia, as well as 
the identification of the factors secreted by PDAC cells causing muscle atrophy, both in vitro and in 
vivo. 
 
 
Conflict of interest. 
The author declares no conflict of interest. 
 
 
Acknowledgements 
 
PEP is supported by Italian Ministry for University and Research (MIUR, Rita Levi-Montalcini 
program for young researchers, 2014), NF is the recipient of a Fondazione Cariplo grant (2015-0634). 
We are grateful to Dr. Riccardo Taulli, Prof. Maurizio Giustetto and Prof. Stefano Geuna for helpful 
discussions and access to instrumentations, and to Erica Mina and Edoardo Ratto for valuable 
technical support. 
 
 
 
 
  
 
 
LEGEND 
 
Figure 1. Characterization of an in vitro and in vivo model of cancer-associated atrophy. C2C12 
myotubes treated for 48 h with 10% conditioned medium (CM) from KPC cells. Dexamethasone 
(DEXA) was used as a positive control of atrophy induction. Pictures were acquired at the bright field 
microscope and (A) diameters were measured. (B) Increased ROS production in C2C12 myotubes 
treated with CM from KPC using oxidant-sensitive fluorescent dye H2DCFDA. (C) No difference in 
food intake in tumor-bearing vs. control mice at the end of experiment, (D) no significant weight loss 
in KPC tumor-bearing vs. control mice. (E) Average tumor weight (Min Max Box Plot). Upon tumor 
growth at the end stage, mice presented reduced muscular resistance as evidenced by (F) performance 
at the hanging test (reach/fall assay) and (G) maximal strength as performed by grip test of upper-
limbs. All experiments have been performed with N # 4 mice per group. All data are shown as means 
± s.e.m; n.s.= non significant; * P < 0.05; *** P < 0.001; using one-way ANOVA with Bonferroni 
correction (A), Two-way ANOVA with Dunnett's multiple comparison test for (E), and Student T-
Test for (B, C, D, F, and G). 
   
 
Figure 2. KPC cell injection promotes skeletal muscle atrophy. (A) Gastrocnemius weight normalized 
on tibia length. (B) H&E representative pictures of muscle sections from control and KPC-injected 
mice. (C-E) Gastrocnemius myofiber membranes were stained for laminin, pictures of whole muscle 
section were acquired and cross sectional area (CSA) were measured (C). (D) Frequency histogram 
showing distribution of myofibers CSA in control and KPC-bearing mice. N = 4 (E) Representative 
pictures of laminin staining for CSA analysis in control and KPC-bearing mice.  (F-I) KPC injection 
does not upregulate atrogene expression. N # 4.  (J) Increased protein ubiquitination and AMPK 
(T172) phosphorylation in mice bearing tumor, blot representative of three independent experiments. 
All data are shown as means ± s.e.m. Statistical analyses was conducted using two tailed t-test. n.s.= 
non significant.  
 
 
 
Figure 3. Metabolic dysregulation of skeletal muscle in KPC-bearing mice. (A) Representative 
images for succinate dehydrogenase (SDH) activity stain. (B) Gastrocnemius mitochondria were 
isolated and ETC activity from Complex I to Complex III assessed by evaluating cytochrome C 
reduction.  (C) 14C-labeled palmitate was used as a substrate to measure Lipid Beta-Oxidation in 
isolated mitochondria of gastrocnemius from control and KPC-bearing mice. (D) Representative T1-
weighted MR images (brightest regions in T1-weighted MR images correspond to adipose regions) 
and (E) in vivo measurement of adipose tissue using MR images in control group vs. KPC–bearing 
mice. (F) Weight of inguinal fat normalized on tibia length for control vs. KPC-bearing mice. (G) 
Gastrocnemius mitochondria were isolated and ATP level was assessed using ATPlite kit (Perkin 
Elmer, USA). (H) ROS measurement in isolated mitochondria from gastrocnemius using H2DCFDA. 
N # 4. All data are shown as means ± s.e.m. Statistical analysis was conducted using two-tailed t-test. 
n.s.= non significant; * P < 0.05; ** P < 0.01; *** P < 0.001. 
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